Waheeda Owadally

[Waheeda Owadally @WOwadally]

@eminowicz Congratulations Gemma!

[Tom Newsom-Davis @tnewsomdavis]

Great talk from Toby Campbell: communicating immunotherapy toxicities to patients

😞 Current pt info often overwhelming
😞 Toxicities unpredictable

✅ Use both verbal & visual approaches
✅ Simple figures
✅ How to describe risk + symptom
✅ Take photo & send to pt

#ASCO24

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

#ASCO24 is ready to start soon! Here, my top🔟 selection with explanation, among the #LungCancer abstracts #LCSM 🧵

[gilberto lopes @GlopesMd]

My top #ASCO24 #LCSM abstracts!
(Nine, not ten, because irs Saturday)

Top 10 Lung

1.Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. LBA4
https://t.co/AXHaa7H7sI

2.Durvalumab +/- tremelimumab as consolidation therapy for patients with limited-stage small-cell lung cancer (LS-SCLC): Results from the phase 3 ADRIATIC study.
https://t.co/dRh8WEaOyh

3.KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. LBA8509
https://t.co/Ng1YgzySAU

4.Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.
https://t.co/QjOCDvMrkT

5.Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
https://t.co/BySMq1GEeC

6.Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. LBA 8505
https://t.co/O6UrOaowZr

7.Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. Abstract 8508
https://t.co/q1Srb6cvUP

8.Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study. 8504
https://t.co/sudCSKioFD

9.Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
https://t.co/1hxUIpR117

@GlopesMd @SylvesterCancer @asco @OncoAlert @oncodaily @iaslc

[Jarushka Naidoo @DrJNaidoo]

#ASCO24 is tomorrow!

Lung Cancer Abstracts not to missed👇

My Top 5 Targeted Therapy abstracts, with key data where available

Get your thinking caps on for tomorrow
@ASCO @myESMO @IASLC #ASCOLDP22
#ESMOCorrespondents @Annals_Oncology @LungCommunity @EGFRResisters @KRASKickers

[Waheeda Owadally @WOwadally]

@BookOncology @DrNicolaDavis @Kiran_MH I am sorry I missed it and I read the book as well! Hopefully next time.

[Corinne Faivre-Finn @finn_corinne]

Amazing plenary session #ASCO24 featuring 2 practice-changing #lungcancer trials @ASCO

[Waheeda Owadally @WOwadally]

@petra_jankowska @lizzietoy @gerryhanna @cpeedell Congratulations Petra!

[Waheeda Owadally @WOwadally]

@Zohra_PhD @BookOncology #oncbcdeath I echo this. It does motivate me to read.

[Waheeda Owadally @WOwadally]

@BookOncology #oncbcdeath Very timely. She does mention the pandemic in ‘rabbit the last words’. She has a lot of descriptions of death. Natural disasters, man made, disease. Some gentle some very harrowing. The pandemic ticks a lot of the descriptions.

[Waheeda Owadally @WOwadally]

@BookOncology #oncbcdeath I haven’t read any other books by her. Will check them out. I may stick to prose though.

[Waheeda Owadally @WOwadally]

@BookOncology #oncbcdeath it’s very poignant and resonating. Clever idea to have at the end of the book. Indeed timeless and universal

[Waheeda Owadally @WOwadally]

@BookOncology #oncbcdeath I am not sure my thoughts changed. I felt very sad for him. I wasn’t clear how much his relationship with death stemmed from his tragic childhood and how much was from the mental health condition. They may be intertwined I guess.

[Waheeda Owadally @WOwadally]

@BookOncology #oncbcdeath No, it hasn’t. But I liked some of the descriptions with death being a woman, life giver and life taker. Weary, constant. Something or someone that is always there but invisible.

[Waheeda Owadally @WOwadally]

@BookOncology #oncbcdeath I think maybe it would have been better for me as an audiobook.

[Waheeda Owadally @WOwadally]

@BookOncology #oncbcdeath I struggled with it. I think I probably did what one shouldn’t do. I rushed through the poetry bits. I admit the words flowed. It’s just not my favourite style.

[Waheeda Owadally @WOwadally]

@BookOncology #onbcdeath disorientating, resonating, sad. I wasn’t sure what to expect. I found the change from prose to poetry and between characters a bit disorientating. Parts of it resonated with me.

[Dr Rachel Clarke @doctor_oxford]

This is brilliant on the NHS. This weekend's essential reading. Thanks ⁦@martha_gill
⁩https://t.co/sy6K5rFZaO

[Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD]

The MOST impactful slide today.
Partnering with Patients is MOST important @ASCOPres #ASCO23

[Jarushka Naidoo @DrJNaidoo]

#ASCO23 KN671

Ph III neoadj chemo-pembro + 1 yr adjuvant IO in early stage NSCLC

- screened >1300pts
- 84%pts completed 3 neoadj cycles, 75% 4 cycles
- EFS HR 0.58.
- pCR 18 v 4%
- OS data not mature, but curves separate

Wowsers
⁦@OncoAlert⁩ @asco ⁦@HwakeleeMD⁩